Back to Search
Start Over
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings
- Source :
- Quality of Life Research
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Background Pembrolizumab (PEMBRO) and ipilimumab + nivolumab (IPI + NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited health-related quality of life (QoL) real-world evidence with immunotherapies in AM, we compared QoL in AM patients receiving either treatment in clinical practice. Methods A prospective US observational study enrolled adult AM patients initiating first-line PEMBRO or IPI + NIVO between June 2017 and March 2018. Endpoints included the QLQ-C30 global health score (GHS) and EuroQol visual analog scale (EQ-VAS) scores. Mean changes were compared using repeated measures mixed-effects models and are presented covariate adjusted. Results 225 PEMBRO and 187 IPI + NIVO patients were enrolled. From baseline through week 24, PEMBRO was associated with 3.2 mean GHS score increase (95% CI 0.5, 5.9; p = .02), while no change was observed with IPI + NIVO; 0.2 (95% CI − 2.6, 3.0; p = 0.87). Among objective treatment-responders, GHS scores associated with PEMBRO increased 6.0 (95% CI 3.1, 8.8; p p = .01). In treatment non-responders, IPI + NIVO was associated with GHS/QoL deterioration of − 3.7 (95% CI − 6.8, − 0.6; p = .02), PEMBRO non-responders demonstrated no change; 0.7 (95% CI − 2.3, 3.7; p = 0.6). Between treatments, PEMBRO patients increased 2.6 greater in EQ-VAS (95% CI 0.6, 4.5; p = .01) vs IPI + NIVO at 24 weeks. Conclusions PEMBRO was associated with better 24-week QoL compared to IPI + NIVO in actual clinical practice settings. Real-world data has known limitations, but with further confirmation these results may have implications for treatment selection.
- Subjects :
- Male
Quality of life
medicine.medical_specialty
Visual analogue scale
medicine.medical_treatment
Pembrolizumab
Article
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
Prospective Studies
030212 general & internal medicine
Melanoma
Patient reported outcomes
Advanced melanoma
business.industry
Public health
Public Health, Environmental and Occupational Health
Repeated measures design
Immunotherapy
Middle Aged
030220 oncology & carcinogenesis
Metastatic
Female
Observational study
business
Subjects
Details
- ISSN :
- 15732649 and 09629343
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Quality of Life Research
- Accession number :
- edsair.doi.dedup.....119e9bb144a339d1f772cb604809ecf6